Old disease, new targets Part-II, haematological malignancies

Shiyam Kumar, Nehal Masood, Salman Naseem Adil

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


In last two decades newer therapies in cancer treatment have emerged and have opened new horizons. New term of targeted therapy has emerged and for certain malignancies the paradigm has really changed after the introduction of these agents. We have learnt and have seen the outcome of some diseases after the addition of these monoclonal antibodies (MoABs) and tyrosine kinase inhibitors (TKIs). Rituximab a MoAB against CD-20 has really paved its role in the treatment of B-cell lymphomas and become the sort of standard therapy. The TKIs are newer agents available in a pill form and have inhibited many pathways at cellular level which are necessary for cancer development. Imatinib has really changed the prognosis and outcome of chronic myeloid leukemia (CML) remarkably. For those patients who develope intolerance to imatinib or their disease became resistant to the imatinib the newer agents like dasatinib and nilotinib are second line options. The major edge of these newer agents is more potency with low side-effect profile. The major concern remains the cost.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalJournal of the Pakistan Medical Association
Issue number8
Publication statusPublished - Aug 2009


Dive into the research topics of 'Old disease, new targets Part-II, haematological malignancies'. Together they form a unique fingerprint.

Cite this